Cue Biopharma Stock Revenue
| CUE Stock | USD 1.04 0.04 3.70% |
Cue Biopharma fundamentals help investors to digest information that contributes to Cue Biopharma's financial success or failures. It also enables traders to predict the movement of Cue Stock. The fundamental analysis module provides a way to measure Cue Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cue Biopharma stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 5.5 M | 3.6 M |
Cue | Revenue |
Cue Biopharma Company Revenue Analysis
Cue Biopharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Cue Biopharma Revenue | 5.49 M |
Most of Cue Biopharma's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cue Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Cue
Projected quarterly revenue analysis of Cue Biopharma provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Cue Biopharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Cue Biopharma's stock price.
Cue Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Cue Biopharma is extremely important. It helps to project a fair market value of Cue Stock properly, considering its historical fundamentals such as Revenue. Since Cue Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cue Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cue Biopharma's interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Cue Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Cue Biopharma reported 5.49 M of revenue. This is 99.93% lower than that of the Biotechnology sector and 99.26% lower than that of the Health Care industry. The revenue for all United States stocks is 99.94% higher than that of the company.
Cue Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cue Biopharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cue Biopharma could also be used in its relative valuation, which is a method of valuing Cue Biopharma by comparing valuation metrics of similar companies.Cue Biopharma is currently under evaluation in revenue category among its peers.
Cue Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Cue Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cue Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cue Biopharma's value.| Shares | Bank Of America Corp | 2024-09-30 | 239.2 K | Stifel Financial Corp | 2024-09-30 | 194.2 K | State Street Corp | 2024-09-30 | 177.1 K | Northern Trust Corp | 2024-09-30 | 138.3 K | Jane Street Group Llc | 2024-06-30 | 98.6 K | Hightower Advisors, Llc | 2024-09-30 | 83.3 K | Ubs Group Ag | 2024-09-30 | 74.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 33.7 K | Xtx Topco Ltd | 2024-09-30 | 27.7 K | Bleichroeder Lp | 2024-09-30 | 5 M | Slate Path Capital Lp | 2024-09-30 | 2.4 M |
Cue Fundamentals
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.91) % | ||||
| Current Valuation | 42.98 M | ||||
| Shares Outstanding | 63.35 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 23.59 % | ||||
| Number Of Shares Shorted | 1.08 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.60 X | ||||
| Price To Sales | 7.94 X | ||||
| Revenue | 5.49 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (46.05 M) | ||||
| Net Income | (50.73 M) | ||||
| Cash And Equivalents | 66.13 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 14.7 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 8.29 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (39.96 M) | ||||
| Short Ratio | 1.54 X | ||||
| Earnings Per Share | (0.91) X | ||||
| Target Price | 3.6 | ||||
| Number Of Employees | 53 | ||||
| Beta | 1.8 | ||||
| Market Capitalization | 65.88 M | ||||
| Total Asset | 61.53 M | ||||
| Retained Earnings | (301.19 M) | ||||
| Working Capital | 34.37 M | ||||
| Current Asset | 42.21 M | ||||
| Current Liabilities | 3.38 M | ||||
| Net Asset | 61.53 M |
About Cue Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cue Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cue Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cue Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Cue Biopharma Piotroski F Score and Cue Biopharma Altman Z Score analysis. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.